Reporting of adverse events in randomized controlled trials of highly active antiretroviral therapy: systematic review (Q33455278)

26 July 2017

1 reference

title

Reporting of adverse events in randomized controlled trials of highly active antiretroviral therapy: systematic review (English)

1 reference

26 July 2017

anti-retroviral agent

0 references

1 reference

3

Leonard Leibovici

1 reference

26 July 2017

6

Mical Paul

1 reference

26 July 2017

5

Steen Andreassen

1 reference

26 July 2017

1

Michal Y Chowers

1 reference

26 July 2017

Bat Sheva Gottesman

2

1 reference

PubMed ID

19477890

26 July 2017

Ulrike Pielmeier

series ordinal

4

1 reference

PubMed ID

19477890

26 July 2017

language of work or name

English

0 references

publication date

28 May 2009

1 reference

Journal of Antimicrobial Chemotherapy

26 July 2017

1 reference

26 July 2017

64

1 reference

26 July 2017

2

1 reference

26 July 2017

239-250

1 reference

Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis

26 July 2017

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.239

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.239

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.239

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.239

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.239

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.239

Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.239

Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.239

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.239

Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.239

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.239

Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.239

A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.239

Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.239

Fluorouracil therapy in patients with carcinoma of the large bowel: a pharmacokinetic comparison of various rates and routes of administration

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.239

Oral cancer treatment: developments in chemotherapy and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.239

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.239

5-Fluorouracil: mechanisms of action and clinical strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.239

Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.239

Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.239

Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.239

Severe sequence-specific toxicity when capecitabine is given after Fluorouracil and leucovorin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.239

Weekly 5-fluorouracil and leucovorin: achieving lower toxicity with higher dose-intensity in adjuvant chemotherapy after colorectal cancer resection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.239

Potential regional differences for the tolerability profiles of fluoropyrimidines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.239

XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.239

Capecitabine (Xeloda) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.239

Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.239

Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.239

Capecitabine and irinotecan as first-line treatment of advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.239

Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.239

Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.239

Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.239

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.239

A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.239

Capecitabine as adjuvant treatment for stage III colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.239

Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.239

The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.239

Phase III Study of Capecitabine Plus Oxaliplatin Compared With Continuous-Infusion Fluorouracil Plus Oxaliplatin As First-Line Therapy in Metastatic Colorectal Cancer: Final Report of the Spanish Cooperative Group for the Treatment of Digestive Tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.239

Phase III Trial of Capecitabine Plus Oxaliplatin As Adjuvant Therapy for Stage III Colon Cancer: A Planned Safety Analysis in 1,864 Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.239

21 January 2018

Identifiers

DOI

10.2217/14750708.6.2.239

1 reference

26 July 2017

1 reference

PubMed ID

19477890